Clinical trial • Phase III • Musculoskeletal
CNTX-0066 for Knee osteoarthritis | Osteoarthritis of the knee
Phase III trial of CNTX-0066 for Knee osteoarthritis | Osteoarthritis of the knee.
Overview
- Trial Therapeutic Area
- Musculoskeletal
- Trial Disease
- Knee osteoarthritis | Osteoarthritis of the knee
- Trial Stage
- Phase III
Key dates
- Initial CTIS Submission Date
- 13-11-2025
- First CTIS Authorization Date
- 24-02-2026
Trial design
Randomised, placebo (single intra-articular injection); dose/schedule not specified-controlled Phase III trial across 1 site in Denmark.
- Randomised
- Yes
- Comparator
- Placebo (single intra-articular injection); dose/schedule not specified
- Target Sample Size
- 20
Eligibility
Recruits 20 Vulnerable population selected; no details provided about consent or assent handling..
- Vulnerable Population
- Vulnerable population selected; no details provided about consent or assent handling.
Recruitment
- Planned Sample Size
- 20
- Recruitment Window Months
- 7
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 20
Denmark
- Earliest CTIS Part Ii Submission Date
- 12-02-2026
- Latest Decision Or Authorization Date
- 24-02-2026
- Processing Time Days
- 12
- Number Of Sites
- 1
- Number Of Participants
- 20
Sites
- Site Name
- Sanos A/S
- Department Name
- Clinical department
- Principal Investigator Name
- Peter Alexandersen
- Principal Investigator Email
- pal@sanosclinic.com
- Contact Person Name
- Peter Alexandersen
- Contact Person Email
- pal@sanosclinic.com
Sponsor
Primary sponsor
- Full Name
- Centrexion Therapeutics Corp.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- CNTX-0066
- Routes Of Administration
- Intra-articular injection
- Route
- Intra-articular
- Frequency
- Single injection
Related trials
Other published trials that may interest you.